Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Dimethyl fumarate (DMF) is one of the newer additions to the armamentarium of potent immunomodulators for the treatment of relapsing-remitting multiple sclerosis (RRMS). After more than 2 years of real-world experience and more than 190,000 patients currently treated with DMF worldwide, it is a good timepoint to review the experience gathered so far and to re-evaluate the potential of this first-line oral multiple sclerosis (MS) drug. Post-hoc analyses of clinical and magnetic resonance imaging (MRI) data, some comprising more than 6 years of drug exposure including patients from the clinical trials, and the overall notion in clinical practice widely confirm the good efficacy of DMF in RRMS. Despite an overall good safety profile, it became also clear that the necessary clinical vigilance while using DMF may not be neglected. So far, four reported cases of progressive multifocal leukoencephalopathy (PML), a towering shadow over many MS therapies, warrant proper attention in newly-updated risk management plans. This review recapitulates efficacy and safety aspects of DMF therapy in relation to reported data from the pivotal clinical trials. In addition, we summarize recent insights into DMF mechanisms of action drawn from the field of basic research which may have important implications for clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155
Self-citationBrennan, M. S., Matos, M. F., Li, B., Hronowski, X., Gao, B., Juhasz, P., Rhodes, K. J., & Scannevin, R. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120254 · Cited by 188
Cited by
Natural products in drug discovery: advances and opportunities
Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., Taskforce, T. I. N. P. S., Orhan, I. E., Banach, M., Rollinger, J. M., Barreca, D., Weckwerth, W., Bauer, R., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00114-z · Cited by 5,392
The expanding role of prodrugs in contemporary drug design and development
Rautio, J., Meanwell, N. A., Di, L., & Hageman, M. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.46 · Cited by 767
Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity
Kornberg, M. D., Bhargava, P., Kim, P. M., Putluri, V., Snowman, A. M., Putluri, N., Calabresi, P. A., & Snyder, S. H. (2018) · Science · doi:10.1126/science.aan4665 · Cited by 687
Evolving concepts in the treatment of relapsing multiple sclerosis
Comi, G., Radaelli, M., & Soelberg Sørensen, P. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32388-1 · Cited by 306
Advances and challenges in therapeutic targeting of NRF2
Dinkova-Kostova, A. T., & Copple, I. M. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.12.003 · Cited by 266
Metadata
- Authors
- Linker, R. A., & Haghikia, A.
- Venue
- Therapeutic Advances in Chronic Disease
- Publisher
- SAGE Publications
- Published
- 2016-06-10
- Volume
- 7
- Issue
- 4
- Pages
- 198-207
- ISSN
- 2040-6223 (ISSN-L)
- 2040-6231
- OpenAlex
- W2412164637
- Cited by
- 134
- References
- 2
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy. https://app.cochat.ai/papers/10.1177/2040622316653307
- The paper
- Linker, R. A., & Haghikia, A. (2016). Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy. Therapeutic Advances in Chronic Disease. https://doi.org/10.1177/2040622316653307
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.